STOCK TITAN

Artivion Inc - AORT STOCK NEWS

Welcome to our dedicated news page for Artivion (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Artivion's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Artivion's position in the market.

Rhea-AI Summary
Artivion, Inc. (AORT) to participate in Oppenheimer Healthcare Conference. Virtual fireside chat on aortic disease scheduled for March 13, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
conferences
-
Rhea-AI Summary
Artivion, Inc. (AORT) reports a strong financial performance in Q4 2023, with revenue reaching $93.7 million, a 15% increase YoY. The company achieved revenue of $354.0 million for the full year 2023, showing a 12% growth on a non-GAAP constant currency basis. Despite a net loss in Q4, non-GAAP net income was $4.6 million. Artivion also closed a $350.0 million credit agreement and presented positive results from the AMDS PERSEVERE clinical trial. The company projects revenue growth of 8-12% in 2024, aiming for non-GAAP adjusted EBITDA to be in the range of $68 to $72 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
earnings
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT), a cardiac and vascular surgery company, will release its Q4 and full year 2023 financial results on February 15, 2024. A teleconference call and webcast will be held to discuss the results, hosted by Pat Mackin, the Chairman, President, and CEO. The press release will contain financial and statistical information for the completed quarter and full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
earnings
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) presents results from the AMDS PERSEVERE clinical trial, demonstrating a 72% reduction in all-cause mortality and a 52% reduction in primary major MAEs at 30 days compared to the current standard of care. The trial also showed statistically significant reduction in all-cause mortality and primary major adverse events, as well as excellent results for secondary endpoints. The AMDS device significantly reduces 30-day MAEs in ADTI patients complicated by malperfusion and helps prevent DANE, with no occurrence of distal anastomotic new entry. The company is excited to deliver this revolutionary technology to patients with no comparable alternatives as soon as possible.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
none
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) has closed a $350 million non-dilutive credit agreement with Ares Management Credit funds, consisting of senior secured, interest-only credit facilities with 6-year maturities. The agreement includes an initial $190 million term loan, a $60 million revolving credit facility, and an additional $100 million in unfunded delayed draw term loan commitments. The company plans to use the funds to address debt maturities and optimize its capital structure. The agreement reflects the company's confidence in its business outlook and aims to deliver significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
none
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) has closed a $350 million non-dilutive credit agreement with Ares Management Credit funds, consisting of senior secured, interest-only credit facilities with 6-year maturities. The agreement includes an initial $190 million term loan, a $60 million revolving credit facility, and an additional $100 million in unfunded delayed draw term loan commitments. The company plans to use the funds to address debt maturities and optimize its capital structure. The agreement reflects the company's confidence in its business outlook and aims to deliver significant shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) appoints Lance A. Berry as Chief Financial Officer, reaffirms financial guidance for 2023. Mr. Berry brings extensive experience from Wright Medical Group N.V. and a strong track record in driving shareholder value. He replaces retiring CFO D. Ashley Lee, who played a pivotal role in the Company's significant growth since 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
management
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) completes enrollment in the PERSEVERE clinical trial for the AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissection, aiming for FDA premarket approval. Dr. Wilson Szeto praises the potential of AMDS as a practice-changing advancement, while Pat Mackin expresses optimism for achieving PMA approval in the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
none
-
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announces participation in Stifel 2023 Healthcare Conference on November 15, 2023, and Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 16, 2023. Management will present at the Lotte New York Palace and host one-on-one meetings, providing insights into the company's cardiac and vascular surgery focus on aortic disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.98%
Tags
conferences
Rhea-AI Summary
Artivion, Inc. (NYSE: AORT) announced its financial results for Q3 2023. The company achieved revenue of $87.9 million, a 14% increase on a GAAP basis and 12% increase on a non-GAAP constant currency basis compared to Q3 2022. Non-GAAP adjusted EBITDA increased 34% to $13.9 million. Aortic stent graft revenues increased 30% and On-X revenues increased 14% compared to Q3 2022. The company is nearing completion of enrollment in the PERSEVERE clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.88%
Tags
earnings
Artivion Inc

NYSE:AORT

AORT Rankings

AORT Stock Data

891.70M
34.32M
5.3%
87.91%
6.54%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Kennesaw

About AORT

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica